GlassScriptPhysician profile
Maria E Garcia
NPI 1871537977
$3,233.12
in general payments reported to CMS, 2019-2025
36 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $349 · 2021: $540 · 2022: $429 · 2023: $606 · 2024: $399 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $528.26 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $246.99 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $232.77 | 2020-2024 | |
| Novo Nordisk INC | $199.60 | 2020-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $196.57 | 2020-2024 | Mounjaro |
| Amarin Pharma, INC. | $188.50 | 2019-2021 | |
| Esperion Therapeutics, INC. | $178.58 | 2020-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $140.13 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $125.91 | 2022 | |
| Merck Sharp & Dohme LLC | $121.53 | 2019 | |
| Glaxosmithkline, LLC. | $114.82 | 2019-2024 | Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.69 | 2019-2025 | Xifaxan |
| Arbor Pharmaceuticals, INC. | $80.43 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $77.40 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $76.94 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $53.88 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.97 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $51.49 | 2019-2021 | |
| Inspire Medical Systems, INC. | $48.46 | 2023 | Inspire |
| Allergan, INC. | $36.49 | 2019-2020 | |
| Pfizer INC. | $35.78 | 2019-2020 | |
| Viatris Specialty LLC | $35.77 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.70 | 2019-2021 | |
| Shield Therapeutics INC | $34.87 | 2023-2024 | Accrufer |
| Sumitomo Pharma America, INC. | $34.10 | 2024 | Gemtesa |
| Shire North American Group INC | $33.65 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $31.61 | 2025 | Dupixent |
| Boston Scientific Corporation | $30.46 | 2022-2023 | Watchman Access System |
| Baxter Healthcare | $21.82 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Astellas Pharma US INC | $18.89 | 2020 | |
| Dexcom, INC. | $17.94 | 2021 | |
| Eisai INC. | $14.24 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.20 | 2021 | |
| Gilead Sciences, INC. | $13.82 | 2023 | |
| Bardy Diagnostics, INC. | $13.57 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.